PostEra and Amgen Collaborate on Research Using Artificial Intelligence for Small Molecule Therapeutics Discovery
Friday, November 17, 2023
PostEra, a biotechnology company specializing in artificial intelligence for preclinical drug discovery, has recently announced a comprehensive collaboration with Amgen, a prominent biotechnology company.
This collaboration aims to utilize PostEra's AI platform, Proton, a groundbreaking advancement in generative chemistry and synthesis-aware design, in conjunction with Amgen's expertise in drug discovery. The joint effort is set to advance up to five small molecule programs. Additionally, as part of the collaboration, Amgen will gain access to some of PostEra's key AI technologies for its internal programs, extending beyond the initial collaboration.
The agreement encompasses upfront funding, milestone payments, and royalties on all approved products resulting from the collaborative efforts.
Expressing enthusiasm about the collaboration, Dr. Alpha Lee, Director of Research and Development at PostEra, highlighted Amgen's expertise in various therapeutic areas and their successful history in addressing challenging biological targets. Dr. Lee emphasized the consistent effectiveness of the Proton platform in tackling complex small molecule drug discovery programs.
Aaron Morris, CEO of PostEra, underscored the transformative potential of AI in drug discovery. He emphasized the company's dedication to proving the value of Proton through real-world discovery programs with multiple partners across diverse therapeutic areas. Morris stated, "We believe that AI can significantly enhance drug discovery, and we have actively demonstrated the value of Proton in collaboration with multiple partners."
This collaboration signifies the growing acknowledgment of AI's role in advancing drug discovery and the commitment of both companies to harnessing innovative technologies for the development of novel therapeutic solutions.
Source: prnewswire.com
